Shots:

• The SYROS study involves assessing of respiratory function evolution during periods of treatment with idebenone (900 mg/day) (On-Idebenone) compared to period without idebenone treatment (Off-Idebenone) in 18 patients with DMD not using glucocorticoids under Expanded Access Programs following P-III DELOS study- published in Neuromuscular Disorders
• The SYROS study results demonstrated long-term efficacy in slowing respiratory function loss (4.2yrs.)- 50% reduction in in FVC%p in Off-Idebenone patients (-7.4% vs -3.8%)- reduction in PEF%p (-5.9% vs -1.9%)- reduction in the rate of bronchopulmonary AE (0.10 vs 0.33 events per person-year)- reduction in rate of hospitalization (0.06 vs 0.15 events per person-year)
• Idebenone is a chemical analog of benzoquinone and a co-factor for quinone oxidoreductase (NQO1) and has received the ODD designation in Europe- the US- Switzerland & Australia and an FT designation by the US FDA

Click here to­ read full press release/ article | Ref: Santhera | Image: Santhera